Published in Vaccine Weekly, February 9th, 1998
The drug regimen, in which three different agents that block HIV replication are given concurrently, has been shown to lower levels of the virus in many patients to levels undetectable by all but the most sensitive assays. Immune system function often is restored in individuals receiving this therapy, returning them to health. They cannot be considered cured, however, because the virus lingers quiescently in certain subpopulations of T cells.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.